Hans Bojar

Biochemistry, Genetics and Molecular Biology · Life Sciences

26h-index2.8kcitations154works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(29), Estrogen and related hormone effects(25), Cancer Genomics and Diagnostics(17), HER2/EGFR in Cancer Research(13), Cancer Cells and Metastasis(11)

Publications154 total

Supplementary Tables 1-3 from A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin κ C as a Compatible Prognostic Marker in Human Solid Tumors
2023Open Access
Data from A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin κ C as a Compatible Prognostic Marker in Human Solid Tumors
2023Open Access
Data from ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and Prediction
2023Open Access
Supplementary Data from ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and Prediction
2023Open Access
CCR Translation for This Article from A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin κ C as a Compatible Prognostic Marker in Human Solid Tumors
2023Open Access
Supplementary Materials and Methods from A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin κ C as a Compatible Prognostic Marker in Human Solid Tumors
2023Open Access
Supplementary Figures 1-11 from A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin κ C as a Compatible Prognostic Marker in Human Solid Tumors
2023Open Access
Supplementary Data from ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and Prediction
2023Open Access
Supplementary Figures 1-11 from A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin κ C as a Compatible Prognostic Marker in Human Solid Tumors
2023Open Access
Data from A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin κ C as a Compatible Prognostic Marker in Human Solid Tumors
2023Open Access
Data from ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and Prediction
2023Open Access
Supplementary Tables 1-3 from A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin κ C as a Compatible Prognostic Marker in Human Solid Tumors
2023Open Access
CCR Translation for This Article from A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin κ C as a Compatible Prognostic Marker in Human Solid Tumors
2023Open Access
Supplementary Materials and Methods from A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin κ C as a Compatible Prognostic Marker in Human Solid Tumors
2023Open Access
Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers – a retrospective study of a single institution
Cancer Immunology Immunotherapy·2020· 40 citedOpen Access
Correction to: The role of passive immunization in the age of SARS-CoV-2: an update
European journal of medical research·2020· 2 citedOpen Access
Präoperative Strahlentherapie (PRT) und Systemtherapie beim Mammakarzinom – welche Faktoren beeinflussen das Gesamtüberleben (OS)?
Geburtshilfe und Frauenheilkunde·2020
Präoperative Strahlentherapie beim Mammakarzinom mit Indikation für eine neoadjuvante Chemotherapie-inwieweit wird durch die präoperative Radiotherapie die pCR-Rate beeinflusst?
Geburtshilfe und Frauenheilkunde·2020
P08.01 Low-dose checkpoint inhibitors with hyperthermia and IL-2 are safe and effective in stage IV cancer with unfavorable immunological profile (MSI<sup>low</sup>, PD-L1 under 1%, TMB<sup>low</sup>) – A single-institution experience from 2015 to 2020
2020Open Access
The role of passive immunization in the age of SARS-CoV-2: an update
European journal of medical research·2020· 33 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Olga Modlich(7), Wilfried Budach(7), Willi Sauerbrei(6), Claudia Schmoor(6), Werner Audretsch(6), Edwin Bölke(6), Matthias Peiper(6), Ralf Kronenwett(5), Martin Schumacher(5), Christiane Matuschek(5), Peter Arne Gerber(5), W. Staib(5), Hans-Bernd Prisack(4), Christiaan Karreman(4), Guido Lammering(4), Klaus Orth(4), Mathias Gehrmann(3), Jan C. Brase(3), Marc‐Oliver Grimm(3), Christian Liebau(3)